Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17889259 | 1.00 | FPR2 (0.42) | FPR2GSK3AGSK3BMITFALDH1A1 | |
| SCHEMBL17889247 | 0.87 | FPR2 (0.43) | FPR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL17889248 | 0.87 | FPR2 (0.43) | FPR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23047608 | 0.86 | FPR2 (0.44) | FPR2GSK3AGSK3BMITFALDH1A1 | |
| SCHEMBL16607262 | 0.83 | LMNA (0.52) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL16607297 | 0.83 | ALDH1A1 (0.46) | FPR2GSK3AGSK3BMITFALDH1A1 | |
| SCHEMBL17889274 | 0.83 | FPR2 (0.41) | FPR2ALDH1A1KDM4ESMN1; SMN2OPRD1 | |
| SCHEMBL17889273 | 0.83 | FPR2 (0.41) | FPR2ALDH1A1KDM4ESMN1; SMN2OPRD1 | |
| SCHEMBL15758840 | 0.81 | SMN1; SMN2 (0.39) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15758042 | 0.81 | SMN1; SMN2 (0.39) | ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511003-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3511002-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-08-19 | — | — | EP | disclosed |
| EP-3050877-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3511003-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511002-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| US-10117853-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2018-11-06 | — | — | US | disclosed |
| US-20180104221-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2018-04-19 | — | — | US | disclosed |
| EP-3275879-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| EP-3050877-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, OPRL1, CNR1 | FPR2 149/4885GSK3A 1438/4885GSK3B 1330/4885 |
| US-10117853-B2 | Cyclic amine derivative and pharmaceutical use thereof | OPRL1, CNP, PDE7A | FPR2 87/4885GSK3A 2282/4885GSK3B 2707/4885 |
| US-20180104221-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | OPRL1, CNP, AANAT | FPR2 71/4885GSK3A 2360/4885GSK3B 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.